BCM
IBB icon

Beck Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Beck Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Buy
2,050
+47
+2% +$8.08K 0.07% 111
2026
Q1 		$338K Buy
2,003
+220
+12% +$37.6K 0.08% 99
2025
Q4 		$301K Buy
+1,783
New +$290K 0.07% 107
2023
Q2 		– Sell
-13,262
Closed -$1.71M – 116
2023
Q1 		$1.71M Buy
+13,262
New +$1.74M 0.73% 56
2021
Q4 		– Sell
-26,199
Closed -$4.24M – 146
2021
Q3 		$4.24M Buy
26,199
+11,909
+83% +$2M 1.42% 14
2021
Q2 		$2.34M Sell
14,290
-126
-0.9% -$19.4K 0.79% 50
2021
Q1 		$2.17M Sell
14,416
-9
-0.1% -$1.43K 0.82% 52
2020
Q4 		$2.19M Sell
14,425
-1,180
-8% -$169K 0.91% 46
2020
Q3 		$2.11M Sell
15,605
-1,004
-6% -$136K 1.19% 39
2020
Q2 		$2.27M Buy
+16,609
New +$2.12M 1.15% 39
2019
Q3 		– Sell
-7,462
Closed -$814K – 103
2019
Q2 		$814K Sell
7,462
-595
-7% -$63.3K 0.43% 54
2019
Q1 		$901K Buy
8,057
+5,732
+247% +$629K 0.43% 61
2018
Q4 		$224K Sell
2,325
-1,382
-37% -$147K 0.19% 62
2018
Q3 		$452K Hold
3,707
– – 0.19% 78
2018
Q2 		$407K Sell
3,707
-846
-19% -$90.5K 0.2% 69
2018
Q1 		$486K Sell
4,553
-130
-3% -$14.4K 0.22% 73
2017
Q4 		$500K Buy
4,683
+123
+3% +$13.1K 0.22% 77
2017
Q3 		$507K Buy
4,560
+2,364
+108% +$253K 0.24% 71
2017
Q2 		$234K Buy
+2,196
New +$216K 0.12% 92
2016
Q1 		– Sell
-18,300
Closed -$2.06M – 115
2015
Q4 		$2.06M Sell
18,300
-1,719
-9% -$187K 1.21% 29
2015
Q3 		$2.02M Sell
20,019
-4,173
-17% -$501K 1.4% 28
2015
Q2 		$2.98M Buy
24,192
+1,710
+8% +$205K 1.59% 19
2015
Q1 		$2.57M Buy
22,482
+36
+0.2% +$3.97K 1.47% 20
2014
Q4 		$2.27M Buy
22,446
+1,503
+7% +$146K 1.32% 21
2014
Q3 		$1.87M Buy
20,943
+645
+3% +$56.6K 1.32% 20
2014
Q2 		$1.74M Sell
20,298
-5,391
-21% -$425K 1.16% 25
2014
Q1 		$2.07M Sell
25,689
-10,233
-28% -$853K 1.58% 16
2013
Q4 		$2.91M Buy
+35,922
New +$2.55M 2.34% 6

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Beck Capital Management's IBB Position: Q2 2026 in Review

Beck Capital Management increased its iShares Biotechnology ETF (IBB) stake by 2.3% in Q2 2026, buying an estimated $8.08K and bringing the position to 2,050 shares worth $390K. The position accounts for 0.07% of the portfolio, ranked #111.

Beck Capital Management first reported a position in IBB in Q4 2013 and has held it in 28 quarters since. The position peaked at $4.24M in Q3 2021. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Beck Capital Management held 2,050 shares of iShares Biotechnology ETF worth $390K as of Q2 2026.
  • Beck Capital Management bought 47 iShares Biotechnology ETF shares in Q2 2026, an estimated $8.08K.
  • iShares Biotechnology ETF made up 0.07% of Beck Capital Management's portfolio in Q2 2026, its #111 holding.
  • Beck Capital Management first reported a position in iShares Biotechnology ETF in Q4 2013 and has held it in 28 quarters since.
  • Beck Capital Management's iShares Biotechnology ETF position peaked at $4.24M in Q3 2021.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Beck Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.